Atria Investments Inc Increases Position in United Therapeutics Co. (NASDAQ:UTHR)

Atria Investments Inc increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 905 shares of the biotechnology company’s stock after purchasing an additional 56 shares during the period. Atria Investments Inc’s holdings in United Therapeutics were worth $319,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Thrivent Financial for Lutherans lifted its position in shares of United Therapeutics by 33.7% in the third quarter. Thrivent Financial for Lutherans now owns 14,332 shares of the biotechnology company’s stock valued at $5,136,000 after acquiring an additional 3,615 shares in the last quarter. Quest Partners LLC raised its stake in United Therapeutics by 347.7% during the 3rd quarter. Quest Partners LLC now owns 1,249 shares of the biotechnology company’s stock valued at $448,000 after purchasing an additional 970 shares during the period. Pathstone Holdings LLC lifted its holdings in United Therapeutics by 4.1% in the 3rd quarter. Pathstone Holdings LLC now owns 4,118 shares of the biotechnology company’s stock worth $1,476,000 after purchasing an additional 163 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in United Therapeutics in the 3rd quarter worth approximately $344,000. Finally, PNC Financial Services Group Inc. grew its holdings in United Therapeutics by 14.9% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,179 shares of the biotechnology company’s stock valued at $1,139,000 after buying an additional 412 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In related news, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the transaction, the director now directly owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Nilda Mesa sold 255 shares of the stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the sale, the director now directly owns 5,528 shares in the company, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 116,464 shares of company stock worth $42,396,244 over the last quarter. Insiders own 11.90% of the company’s stock.

United Therapeutics Trading Up 5.1 %

UTHR opened at $322.94 on Tuesday. The stock has a 50-day moving average of $349.12 and a 200 day moving average of $358.27. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82. The firm has a market cap of $14.50 billion, a P/E ratio of 14.18, a P/E/G ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the business earned $4.36 EPS. On average, research analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. UBS Group boosted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.